Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 1, 2010, Pages 133-137

  Ozbasar, Demir ^a   Toros, Ummuhan ^a   Ozkaya, Okan ^a   Sezik, Mekin ^a   Uzun, Hafize ^a   Genc, Habibe ^a   Kaya, Hakan ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antioxidant; Hemodialysis; Menopause; Raloxifene; Renal failure

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NITRIC OXIDE; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; RANK SUM TEST; TRIACYLGLYCEROL BLOOD LEVEL; WILCOXON SIGNED RANKS TEST;

AGED; ANTIOXIDANTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; POSTMENOPAUSE; RALOXIFENE; RENAL DIALYSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 76349088964     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01086.x     Document Type: Article

References (34)

1. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004 266 : 37 56.
2. Freeman BA, Crapo JD. Biology of disease: Free radicals and tissue injury. Lab Invest 1982 47 : 412 426.
3. Rangan U, Bulkley GB. Prospects for treatment of free radical-mediated tissue injury. Br Med Bull 1993 49 : 700 718.
4. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001 5 : 88 97.
5. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: An overview. J Cardiovasc Pharmacol 1999 34 : 879 886.
6. Cooke JP. Is atherosclerosis an arginine deficiency disease? J Investig Med 1998 46 : 377 380.
7. Weisinger JR. Role of hormone replacement in the management of osteoporosis in haemodialysed women: Perspectives for the future. Nephrol Dial Transplant 2000 15 : 36 37.
8. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998 9 : 16 23.
9. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991 265 : 1861 1867.
10. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991 20 : 47 63.
11. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995 332 : 1589 1593.
12. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998 280 : 605 613.
13. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000 343 : 522 529.
14. Rossouw JE, Anderson GL, Prentice RL et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 2002 288 : 321 333.
15. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998 279 : 1445 1451.
16. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: A look ahead. Drugs 1999 57 : 653 663.
17. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifene in postmenopausal women in vitro. Menopause 2003 10 : 142 146.
18. Wassmann S, Laufs U, Stamenkovic D et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002 105 : 2083 2091.
19. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002 105 : 1368 1373.
20. Rahimian R, Dube GP, Toma W, Dos Santos N, McManus BM, van Breemen C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 2002 434 : 141 149.
21. Ozgonul M, Oge A, Sezer ED, Bayraktar F, Sozmen EY. The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovarectomized female rats. Endocr Res 2003 29 : 183 189. (Pubitemid 36828490)
22. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978 52 : 302 310.
23. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982 126 : 131 138.
24. Dirican M, Sarandol E, Serdar Z, Ocak N, Dilek K. Oxidative status and prevalent cardiovascular disease in patients with chronic renal failure treated by hemodialysis. Clin Nephrol 2007 68 : 144 150.
25. Palleschi S, De Angelis S, Diana L et al. Reliability of oxidative stress biomarkers in hemodialysis patients: A comparative study. Clin Chem Lab Med 2007 45 : 1211 1218.
26. Eiselt J, Racek J, Trefil L, Opatrný K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001 25 : 430 436.
27. Drai J, Bannier E, Chazot C et al. Oxidants and antioxidants in long-term haemodialysis patients. Farmaco 2001 56 : 463 465.
28. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol 2004 24 : 537 542.
29. Chang SP, Yang WS, Lee SK, Min WK, Park JS, Kim SB. Effects of hormonal replacement therapy on oxidative stress and total antioxidant capacity in postmenopausal hemodialysis patients. Ren Fail 2002 24 : 49 57.
30. Ginsburg ES, Owen WF Jr., Greenberg LM, Shea BF, Lazarus JM, Walsh BW. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 1996 81 : 4414 4417.
31. Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, Ulukaya E. Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. Maturitas 2005 50 : 182 188.
32. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002 287 : 847 857.
33. Hernández E, Valera R, Alonzo E et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003 63 : 2269 2274.
34. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 2002 13 : 1918 1927.